Nasus Pharma is trading at $3.53, down -5.88% after opening-session weakness on September 4, 2026.

  • No new company-specific announcement dated September 4 was identified.
  • The investor-relations page lists its latest release on August 19, 2026, concerning a CFO transition.
  • Broader indices are mixed, so market sentiment does not clearly explain the decline.